Income Statement Quanterix Corporation
Equities
QTRX
US74766Q1013
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.720 USD | -0.84% |
|
-6.72% | -25.79% |
| Mar. 02 | Quanterix Corporation, Q4 2025 Earnings Call, Mar 02, 2026 | |
| Mar. 02 | Quanterix Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 111M | 106M | 122M | 137M | 139M | |||||
Total Revenues | 111M | 106M | 122M | 137M | 139M | |||||
Cost of Goods Sold, Total | 48.55M | 58.72M | 51.72M | 54.32M | 73.94M | |||||
Gross Profit | 62M | 46.81M | 70.65M | 83.1M | 64.96M | |||||
Selling General & Admin Expenses, Total | 92.34M | 92M | 90.24M | 102M | 121M | |||||
R&D Expenses | 27.98M | 25.89M | 24.86M | 31.08M | 30.82M | |||||
Other Operating Expenses, Total | 120M | 118M | 115M | 133M | 152M | |||||
Operating Income | -58.31M | -71.08M | -44.45M | -49.6M | -86.57M | |||||
Interest Expense, Total | -403K | - | - | - | - | |||||
Interest And Investment Income | - | 5.13M | 15.84M | 14.66M | 8.57M | |||||
Net Interest Expenses | -403K | 5.13M | 15.84M | 14.66M | 8.57M | |||||
Currency Exchange Gains (Loss) | -835K | - | - | -600K | - | |||||
Other Non Operating Income (Expenses) | - | -62K | - | - | 157K | |||||
EBT, Excl. Unusual Items | -59.55M | -66.01M | -28.61M | -35.54M | -77.85M | |||||
Restructuring Charges | - | -30.62M | -3.71M | -3.02M | -8.84M | |||||
Merger & Related Restructuring Charges | -275K | - | - | - | -12.4M | |||||
Impairment of Goodwill | - | - | - | - | -6.37M | |||||
Asset Writedown | - | - | -1.54M | - | -1.35M | |||||
Other Unusual Items | 2.1M | - | 2.25M | 464K | -5.45M | |||||
EBT, Incl. Unusual Items | -57.72M | -96.64M | -31.62M | -38.1M | -112M | |||||
Income Tax Expense | -36K | 65K | 719K | 434K | -5.12M | |||||
Earnings From Continuing Operations | -57.69M | -96.7M | -32.33M | -38.53M | -107M | |||||
Net Income to Company | -57.69M | -96.7M | -32.33M | -38.53M | -107M | |||||
Net Income - (IS) | -57.69M | -96.7M | -32.33M | -38.53M | -107M | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||
Net Income to Common Incl Extra Items | -57.69M | -96.7M | -32.33M | -38.53M | -107M | |||||
Net Income to Common Excl. Extra Items | -57.69M | -96.7M | -32.33M | -38.53M | -107M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -1.6 | -2.61 | -0.86 | -1 | -2.51 | |||||
Basic EPS - Continuing Operations | -1.6 | -2.61 | -0.86 | -1 | -2.51 | |||||
Basic Weighted Average Shares Outstanding | 36M | 36.99M | 37.59M | 38.37M | 42.64M | |||||
Net EPS - Diluted | -1.6 | -2.61 | -0.86 | -1 | -2.51 | |||||
Diluted EPS - Continuing Operations | -1.6 | -2.61 | -0.86 | -1 | -2.51 | |||||
Diluted Weighted Average Shares Outstanding | 36M | 36.99M | 37.59M | 38.37M | 42.64M | |||||
Normalized Basic EPS | -1.03 | -1.12 | -0.48 | -0.58 | -1.14 | |||||
Normalized Diluted EPS | -1.03 | -1.12 | -0.48 | -0.58 | -1.14 | |||||
Supplemental Items | ||||||||||
EBITDA | -53.46M | -65.73M | -38.09M | -43.13M | -71.93M | |||||
EBITA | -56.31M | -69.28M | -42.85M | -48M | -78.97M | |||||
EBIT | -58.31M | -71.08M | -44.45M | -49.6M | -86.57M | |||||
EBITDAR | -48.06M | -56.83M | -28.88M | -33.82M | -60.26M | |||||
Total Revenues (As Reported) | 111M | 106M | 122M | 137M | 139M | |||||
Effective Tax Rate - (Ratio) | 0.06 | -0.07 | -2.27 | -1.14 | 4.56 | |||||
Current Domestic Taxes | 30K | 77K | 161K | 37K | 93K | |||||
Current Foreign Taxes | 342K | 368K | 850K | 683K | 416K | |||||
Total Current Taxes | 372K | 445K | 1.01M | 720K | 509K | |||||
Deferred Domestic Taxes | 1K | -23K | - | - | -5.25M | |||||
Deferred Foreign Taxes | -409K | -357K | -292K | -286K | -381K | |||||
Total Deferred Taxes | -408K | -380K | -292K | -286K | -5.63M | |||||
Normalized Net Income | -37.22M | -41.26M | -17.88M | -22.21M | -48.65M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | - | - | 300K | 500K | - | |||||
Selling and Marketing Expenses | - | - | 300K | 500K | - | |||||
Research And Development Expense From Footnotes | 27.98M | 25.89M | 24.86M | 31.08M | 37.12M | |||||
Net Rental Expense, Total | 5.4M | 8.9M | 9.2M | 9.31M | 11.66M | |||||
Imputed Operating Lease Interest Expense | 661K | - | - | - | - | |||||
Imputed Operating Lease Depreciation | 4.74M | - | - | - | - | |||||
Stock-Based Comp., COGS (Total) | 874K | 1.43M | 1.95M | 2.27M | 1.87M | |||||
Stock-Based Comp., R&D Exp. (Total) | 1.81M | 1.64M | 1.7M | 2.12M | 2.18M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 13.29M | 12.38M | 13.11M | 15.6M | 16.67M | |||||
Total Stock-Based Compensation | 15.98M | 15.44M | 16.76M | 19.99M | 20.72M |
- Stock Market
- Equities
- QTRX Stock
- Financials Quanterix Corporation
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















